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ABSTRACT
Background. Besides improving glucose control, sodium-glu-
cose co-transporter 2 inhibition with dapagliﬂozin reduces
blood pressure, body weight and urinary albumin:creatinine ra-
tio (UACR) in patients with type 2 diabetes (T2DM). The pa-
rameter response efﬁcacy (PRE) score was developed to predict
how short-term drug effects on cardiovascular risk markers
translate into long-term changes in clinical outcomes. We ap-
plied the PRE score to clinical trials of dapagliﬂozin to model
the effect of the drug on kidney and heart failure (HF) outcomes
in patients with T2DM and impaired kidney function.
Methods. The relationships between multiple risk markers and
long-term outcome were determined in a background popula-
tion of patients with T2DM with a multivariable Cox model.
These relationships were then applied to short-term changes in
risk markers observed in a pooled database of dapagliﬂozin tri-
als (n¼ 7) that recruited patients with albuminuria to predict
the drug-induced changes to kidney and HF outcomes.
Results. A total of 132 and 350 patients had UACR>200mg/g
and >30mg/g at baseline, respectively, and were selected for
analysis. The PRE score predicted a risk change for kidney
events of 40.8% [95% conﬁdence interval (CI) 51.7 to
29.4) and 40.4% (95% CI 48.4 to 31.1) with dapagliﬂo-
zin 10mg compared with placebo for the UACR>200mg/g
and >30mg/g subgroups. The predicted change in risk for
HF events was 27.3% (95% CI 47.7 to 5.1) and 21.2%
(95% CI 35.0 to 7.8), respectively. Simulation analyses
showed that even with a smaller albuminuria-lowering effect of
dapagliﬂozin (10% instead of the observed 35% in both groups),
the estimated kidney risk reduction was still 26.5 and 26.8%,
respectively.
Conclusions. The PRE score predicted clinically meaningful
reductions in kidney and HF events associated with dapagliﬂo-
zin therapy in patients with diabetic kidney disease. These
results support a large long-term outcome trial in this popula-
tion to conﬁrm the beneﬁts of the drug on these endpoints.
Keywords: clinical trial, dapagliﬂozin, diabetic kidney disease,
heart failure, risk markers
INTRODUCTION
Approximately 40% of patients with diabetes develop chronic
kidney disease (CKD) [1]. Both diabetes and CKD are powerful
risk factors for end-stage kidney disease (ESKD) and cardiovas-
cular disease. In addition, emerging data demonstrate a strong
association between diabetes and heart failure (HF). Patients
with both diabetes and impaired kidney function are at particu-
lar high risk to develop HF [2, 3]. As a result, life expectancy
among patients with diabetes and kidney disease and/or HF is
shortened [4]. New therapies to decrease the risks of developing
CKD and HF are being developed.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a
relatively new class of oral anti-diabetic drugs registered for use
in patients with type 2 diabetes (T2DM). Recent cardiovascular
outcome trials have demonstrated that the SGLT2 inhibitors
empagliflozin, canagliflozin and dapagliflozin reduce the risk of
HF and slow kidney disease progression in patients with T2DM
at cardiovascular risk or with established cardiovascular disease
[5–7]. The marked efficacy of these drugs to delay disease pro-
gression is unlikely to be explained by their effects on glycated
haemoglobin [haemoglobin A1c (HbA1c)] alone. Indeed, a
study comparing glimepiride against canagliflozin concluded
that the beneficial effects of canagliflozin in slowing estimated
glomerular filtration rate (eGFR) decline were independent of
its glycaemic effects [8]. Furthermore, in hypertensive patients
with T2DM who were using angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers, HbA1c lowering by
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dapagliflozin only modestly explained the overall 35% reduc-
tion in the urine albumin:creatinine ratio (UACR) [9]. The
multiple effects of SGLT2 inhibition, including reductions in
body weight, blood pressure (BP), albuminuria and uric acid,
in addition to reducing HbA1c, may contribute to the reduction
in HF and kidney events observed in prior studies [9–11].
Because SGLT2 inhibition has effects on multiple cardiovas-
cular risk markers, integrating changes in these multiple effects
as opposed to using HbA1c alone to predict the long-term effect
of SGLT2 inhibitors on kidney and HF outcomes seems sensi-
ble. The multiple parameter response efficacy (PRE) score is an
algorithm that has been developed to translate the effect of an
intervention on multiple risk markers into a predicted long-
term risk change on clinical outcomes [10]. The PRE score was
developed in clinical trials of renin–angiotensin–aldosterone
system (RAAS) intervention and subsequently validated in clin-
ical trials of renin–angiotensin–aldosterone system interven-
tion, peroxisome proliferator-activated receptor c agonists and
endothelin receptor antagonists [12–14].
Randomized controlled trials investigating the long-term
effects of SGLT2 inhibition in patients with CKD are currently
ongoing. The aim of this study was to apply the PRE score to
Phase 3 clinical trials with the SGLT2 inhibitor dapagliflozin in
order to predict the potential benefit of dapagliflozin on kidney
and HF outcomes in patients with T2DM and CKD.
MATERIALS AND METHODS
Data sources and patient population
Individual patient data were selected from a pooled database
of Phase 3 dapagliflozin clinical trials (n¼ 7) with an eGFR
between 25 and 60mL/min/1.73m2 and UACR >30mg/g
(Supplementary data, Table S1). The study designs of these tri-
als have been previously published [15–21]. Patients were then
stratified into two groups, those with UACR >30mg/g
(n¼ 350) and those with UACR>200mg/g (n¼ 132), in order to
test the PRE score at varying levels of albuminuria. Patients with
impaired eGFR and elevated albuminuria were selected, as this
population is also enrolled in the ongoing kidney outcome trials.
Individual patient data from the placebo arm of the Aliskiren
Trial in Type 2 Diabetes Using Cardio-Renal Endpoints
(ALTITUDE) were used for the background population to model
the risk relations for different cardiovascular risk markers with
kidney and HF outcomes. The design of ALTITUDE has been
previously published [22]. This population included patients
with T2DM and CKD (defined as eGFR between 25 and 60mL/
min/1.73 m2) with various degrees of albuminuria [UACR
>30 mg/g (n¼ 2163) and UACR>200 mg/g (n¼ 1341)].
Endpoint definition
The kidney outcome was defined as a composite of ESKD and
a confirmed doubling of serum creatinine. The HF outcome was
defined as hospitalization due to congestive heart failure (CHF).
Risk marker selection
Parameters measured in the intention-to-treat population of
the dapagliflozin Phase 3 trials that were previously identified
as risk markers for kidney or HF outcomes and have been
shown to change with SGLT2 treatment were used for analysis.
These included Glycated haemoglobin (HbA1c), systolic BP,
UACR, body weight, haemoglobin (Hb), high-density lipopro-
tein cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C), serum albumin, calcium, potassium, phosphate and
uric acid. The UACR was measured in an untimed random
spot urine sample.
Statistical analysis
A Cox proportional hazards model was used to estimate the
coefficients and hazard ratios associated with each risk marker
for the first recorded kidney or HF event. The regression coeffi-
cients for each risk marker were taken and used as weights for
the risk equation for kidney and HF outcomes. First, risk
marker–outcome relationships were calculated in ALTITUDE
over a median follow-up of 2.8 years. These calculated risk
marker–outcome relationships were then applied to the base-
line and Week 24 (Month 6) biomarker measurements of
patients selected from the dapagliflozin trials to estimate the
risk of kidney and HF outcomes at both time points. The mean
difference in the predicted risk in the dapagliflozin arm, ad-
justed for the mean difference in the predicted risk in the pla-
cebo arm, represents the PRE score and reflects an estimation
of the expected kidney and HF risk reduction conferred by
dapagliflozin treatment.
Risk marker–outcome relationships were calculated in
patients from the ALTITUDE background population with
UACR >200mg/g (n¼ 1341) and UACR >30mg/g
(n¼ 2641). These relationships were applied to patients in-
cluded in the dapagliflozin Phase 3 trials with UACR>200mg/
g (n¼ 92) and UACR >30mg/g (n¼ 260), respectively. The
PRE score was calculated for subjects in the dapagliflozin Phase
3 trials in which all risk markers were measured at baseline and
follow-up. To evaluate the influence of missing data, we applied
multiple imputations to the data from the dapagliflozin Phase 3
programme by using a multilevel linear model (from the R
package ‘mice’; R Foundation for Statistical Computing,
Vienna, Austria, www.r-project.org). Since the short-term
change in albuminuria is a strong predictor of kidney outcomes,
we performed a simulation analysis to estimate the change in
the risk of kidney outcomes at various levels of albuminuria
reduction.
Means and standard deviations (SDs) are provided for varia-
bles with a normal distribution, whereas medians and first and
third quartiles are provided for variables with a skewed distribu-
tion. Categorical variables are reported as frequencies and percen-
tages. For continuous variables that are not normally distributed,
such as UACR, a natural log transformation was applied before
analysis. Two-sided P-values <0.05 indicated statistical signifi-
cance. All statistical analyses were conducted with R version 3.0.1.
RESULTS
In the background dataset derived from ALTITUDE, 172
(8.0%) patients experienced a kidney event and 120 (5.5%)
patients were hospitalized for CHF during a median follow-up
of 2.8 years.
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Baseline characteristics of the populations from ALTITUDE
and the dapagliflozin trials with UACR >200mg/g and
>30mg/g are described in Table 1 and Supplementary data,
Table S2, respectively.
Short-term changes in risk markers
Changes in risk markers in patients with UACR>200mg/g
after treatment with placebo and dapagliflozin 5 and 10mg are
shown in Figure 1. In line with prior studies in patients with im-
paired kidney function, dapagliflozin modestly reduced HbA1c.
Reductions in body weight, BP, uric acid and UACR and
increases in Hb, albumin and phosphate were also observed.
The direction and magnitude of the short-term changes in risk
markers were similar in patients with UACR> 30mg/g
(Supplementary data, Figure S1).
Predicted treatment effect
In patients with UACR>200mg/g, the predicted risk
change for the kidney endpoint with dapagliflozin based on the
observed placebo-corrected change in HbA1c alone was 0.9%
(1.6–0.0) and2.5% (95% CI4.5 to –0.1) with dapagliflozin
5mg and 10mg, respectively (Figure 2). Based on albuminuria-
lowering effects alone, the predicted risk change in kidney end-
points was34.1% (95% CI39.5 to27.3) and27.7% (95%
CI32.7 to22.0), respectively. Integrating all short-term bio-
marker changes resulted in a predicted risk change of 40.6%
(95% CI 52.3 to 28.9) and 40.8% (95% CI 51.7 to
29.4) with dapagliflozin 5mg and 10mg, respectively. The
predicted risk change for hospitalization due to HF based on
the PRE score was 23.8% (95% CI 43.4 to 4.7) and
27.3% (95% CI47.7 to5.1), respectively.
In patients with UACR >30mg/g, the predicted risk change
for the kidney endpoint was 47.6% (95% CI 55.9 to 37.1)
and 40.4% (95% CI 48.1 to 31.1) after treatment with
dapagliflozin 5mg and 10mg, respectively. The predicted risk
change for hospitalizations due to HF was 23.4% (95% CI
39.1 to 7.4) and 21.2% (95% CI 35.0 to 7.8), respec-
tively (Supplementary data, Figure S1).
Simulations and sensitivity analyses
Since albuminuria change is a strong predictor for kidney
outcomes, additional simulations were performed in order to
predict the risk changes for varying levels of albuminuria
changes induced by dapagliflozin (Figure 3). These simulation
analyses revealed that a 10% decrease in UACR, instead of the
observed decrease of 35%, would have resulted in an estimated
kidney risk reduction of 26.8 and 26.5% in patients with UACR
>200 mg/g and>30mg/g, respectively.
In a sensitivity analysis, we assessed the impact of missing
values. In the dapagliflozin trials, data were missing in 9.5% of
patients at baseline and in 25.1% of patients at Month 6. There
were very few missing baseline data across the ALTITUDE
background dataset (<0.01%). There were no differences in
baseline characteristics between patients with complete bio-
marker data and the total selected population from the dapagli-
flozin trials (n¼ 350). Short-term changes in risk markers in
the analysis population remained similar after multiple imputa-
tions. In patients with UACR >200mg/g, the predicted kidney
risk changes with dapagliflozin 5 and 10mg after multiple im-
putation were 44.1% (95% CI 5.1 to 32.6) and 38.5%
(95% CI 47.2 to 28.7), respectively. The predicted risk
changes for hospitalizations due to HF were 24.0% (95% CI
46.0 to 3.1) and 24.7% (95% CI 43.6 to 5.0),
Table 1. Baseline characteristics of the background population from ALTITUDE and the dapagliﬂozin Phase 3 programme participants included in the











Age (years) 63.0 (9.6) 64.4 (7.7) 63.5 (7.5) 62.0 (9.5) 0.35
Female, n (%) 411 (31) 9 (29) 13 (38) 6 (21) 1.00
Race, n (%) 0.68
Caucasian 641 (48) 27 (87) 26 (77) 24 (86)
Black 47 (4) 0 (0) 1 (3) 2 (7)
Asian 530 (39) 2 (7) 2 (6) 1 (4)
Other 123 (9) 2 (7) 4 (12) 1 (4)
Clinical characteristics
HbA1c (%) 7.8 (1.6) 8.4 (0.9) 8.5 (1.0) 8.2 (0.9) 0.94
Systolic BP (mmHg) 139 (17) 141 (15) 143.2 (19.4) 143.7 (19.6) 0.47
UACR (mg/g), median (IQR) 869 (385–1795) 618 (353–980) 696 (449–1835) 576 (388–1028) 0.23
Weight (kg) 81.0 (19) 98.4 (20) 90.2 (15.0) 99.2 (19.3) 0.31
Hb (g/dL) 12.7 (1.8) 13.4 (1.8) 13.2 (1.3) 13.4 (1.6) 0.76
HDL (mg/dL) 45.9 (13.7) 41.7 (9.5) 39.4 (11.5) 41.8 (8.6) 0.59
LDL (mg/dL) 102.6 (39) 87.9 (32) 106.9 (43.8) 95.1 (36.5) 0.11
Albumin (g/dL) 4.1 (0.4) 4.3 (0.3) 4.0 (0.4) 4.2 (0.3) 0.07
Potassium (mmol/L) 4.6 (0.5) 4.6 (0.4) 4.4 (0.5) 4.6 (0.5) 0.41
Phosphate (mg/dL) 3.8 (0.7) 3.6 (0.5) 3.7 (0.6) 3.8 (0.4) 0.47
Uric acid (mg/dL) 7.2 (1.7) 6.7 (1.7) 7.3 (1.7) 7.5 (1.9) 0.08
Calcium (mg/dL) 9.3 (0.5) 9.6 (0.4) 9.4 (0.5) 9.6 (0.5) 0.17
Values are presented as mean (SD) unless stated otherwise.
aP-value for the difference between placebo and dapagliﬂozin.
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respectively (Supplementary data, Figure S2). After multiple
imputations, predicted risk changes for kidney and HF out-
comes for patients with UACR>30mg/g did not differ from
those in the main analysis without multiple imputations
(Supplementary data, Figure S3).
DISCUSSION
Changes in biomarkers can be used to monitor and predict the
efficacy of therapies to decrease the risk of kidney and cardio-
vascular outcomes. In this study we used an algorithm that
translates the short-term effect of an intervention on multiple
risk markers into a predicted long-term risk change on clinical
outcomes. The algorithm was used to predict the effect of dapa-
gliflozin on kidney and HF outcomes in patients with T2DM
and CKD. Our results indicate that treatment with dapagliflozin
would confer considerable improvements in kidney and HF
outcomes in these patients. These results support a large dapa-
gliflozin outcome trial to confirm long-term safety and efficacy
in reducing adverse clinical events.
As with most short-term clinical trials testing the effects of
SGLT2 inhibitors, the dapagliflozin trials included in this study
were primarily designed to assess the effects of dapagliflozin on
HbA1c [15–17, 19–21, 23]. Our analysis suggests that glycaemic
effects of dapagliflozin only modestly contribute in reducing the
risk of kidney outcomes. Non-glycaemic effects of dapagliflozin,
in particular the albuminuria-lowering properties, are probably
more important contributors of the predicted effects on kidney
outcomes. Indeed, prior studies have suggested that albumin-
uria lowering is a key to reducing kidney outcomes [24, 25].
A meta-analysis of cardiovascular events across the dapagli-
flozin Phases 2b and 3 programmes suggested beneficial effects
of dapagliflozin on cardiovascular and HF outcomes [26]. In
line with these results, empagliflozin reduced the occurrence
of hospitalization for HF by 35% in the Empagliflozin
Cardiovascular Outcome Event Trial in Type 2 Diabetes
Mellitus Patients–Removing Excess Glucose and by 39% in the
subgroup of patients with diabetes and kidney disease [27].
Likewise, another large-scale cardiovascular outcome study, the
Canagliflozin Cardiovascular Assessment Study, reported a de-
crease in hospitalization for HF of 33% in patients randomized
to canagliflozin versus placebo [7]. The recently completed
Dapagliflozin Effect on Cardiovascular Events–Thrombolysis
in Myocardial Infarction 58 trial investigated the effects of
dapagliflozin in patients at high cardiovascular risk and
reported that dapagliflozin reduced the occurrence of the com-
posite kidney outcome by 47%. Furthermore, risk for hospitali-
zation due to HF decreased by 27% on dapagliflozin [5]. A
meta-analysis of the three cardiovascular outcome trials con-
firmed the consistent and strong effect of SGLT2 inhibitors in
reducing the risk of hospitalization for HF and progression of
renal disease [28]. These observed effects are very similar to our
PRE score predictions in patients with elevated albuminuria.
The ongoing Dapagliflozin on Renal Outcomes and
Cardiovascular Mortality in Patients with Chronic Kidney
Disease trial, described in the companion article, will provide a
more clear answer whether the predicted effects of dapagliflozin
in patients with CKD are accurate (clinicaltrials.gov identifier
NCT03036150).
Although the mechanisms underlying the multipotent ac-
tion of SGLT2 inhibitors are not completely understood, several
lines of evidence suggest that the normalization of tubuloglo-
merular feedback plays a key role in the renoprotective effects
[29]. In addition, dapagliflozin-induced natriuretic/osmotic di-
uresis and the resultant volume contraction may contribute to
enhanced fluid clearance from the interstitial space and explain
the reduction in HF risk [30–32]. However, the favourable car-
diorenal effects of dapagliflozin are potentially counterbalanced
by other non-beneficial effects, including alterations in calcium
and phosphate homeostasis [33]. Prior studies have shown
modest increases in phosphate during dapagliflozin therapy




transporter, leading to a reduction in phosphate clearance and
compensatory increases in parathyroid hormone and fibroblast
growth factor 23 [33–35]. The increase in serum phosphate lev-
els observed in our analysis translated into a small increase in
estimated kidney and HF risk. Yet the benefits associated with
improvements in multiple risk markers outweighed this small
increase in risk.
What is the applicability of the PRE score for future clinical
trials and patient care? Changes in single risk markers often in-
sufficiently predict the long-term drug effect on clinical out-
comes, as shown by multiple clinical trials [22, 36–38].
Integrating multiple short-term risk marker changes has the
FIGURE 1: Mean changes in risk markers from baseline to Month 6 in the included population of the dapagliﬂozin Phase 3 programme with
UACR>200mg/g. Changes are presented as mean (695% CI) and are given for placebo, dapagliﬂozin 5mg and dapagliﬂozin 10mg.
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potential to better predict long-term treatment effects [39].
Accurate long-term risk prediction is important to better pre-
dict the long-term effect of a drug in daily patient care as well as
to improve the design of clinical trials. As such, the PRE score
can be used in clinical practice to better predict the long-term
effect of a drug for an individual patient and during early drug
development to determine if a new drug is likely to be effective
and to inform power and sample size calculations [39].
FIGURE 2: Predicted risk change for (A) kidney and (B) HF outcomes for patients with UACR >200mg/g, based on changes in single risk
markers and the integrated effects of all risk markers. Circles indicate the point estimates of the percentage mean change in relative risk in-
duced by dapagliﬂozin compared with placebo and is given with its 95% CI.
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A main limitation of this study is that we could not include
all relevant biomarkers that are associated with kidney and HF
outcomes. For example, we ideally would have used N-terminal
prohormone of brain natriuretic peptide as a marker for volume
status instead of body weight, as the latter may merely represent
initial volume contraction rather than sustained alterations in
fluid handling. In addition, the number of patients with UACR
>200mg/g and eGFR 30–60 mL/min/1.73m2 was relatively
small, which limits the precision of our effect estimates.
Furthermore, some patients did not use concomitant RAAS in-
hibition. In the ongoing kidney outcome trials of SGLT2 inhibi-
tors, nearly all patients are receiving RAAS inhibition. We do
not believe, however, this influences our predictions, as it has
been shown that the effects of dapagliflozin on all cardiovascu-
lar risk markers included in our analysis are consistent regard-
less of concomitant RAAS inhibition [40].
In conclusion, the PRE score predicted clinically meaning-
ful reductions in kidney and HF endpoints associated with
dapagliflozin therapy in patients with diabetic kidney disease.
These results support a large long-term outcome trial in this
population to confirm the benefits of the drug on these
endpoints.
SUPPLEMENTARY DATA
Supplementary data are available at ndt online.
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